Figure 4. FACS analysis with primary HUVECs using anti-Human VEGFR-2 antibody.
Figure 5. Consecutive sections of unfixed, human foreskin. A) Staining with anti-soluble VEGFR2/KDR antibodies ( -L). Note signal in epidermis and vessels. B) Staining with anti-membrane-bound VEGFR-2/KDR. Note staining in vessels. C) Negative control. Note non-specific fluorescence in the hornified layer of the epithelium. Provided by Prof. J. Wilting, GÇŸ¶ôttingen, Germany.
Figure 2. FACS analysis of VEGFR-2/KDR expression in HUVE cells (upper level) and EPCs derived from PBMcs (lower level ) [5ug/ml ; 5ug/ml PE goat anti-mouse IgG]. The experiment was performed by Trisha M. Westerhof, University of California, Irvine.
Figure 1. Up-regulation of VEGFR-2 in primary HUVECs by bFGF: Freshly isolated HUVECs (passage 1) were cultured in EBM. Subconfluent cultures were stimulated with VEGF (5 ng/ml) or bFGF (10 ng/ml) for 3 days. Total lysate was prepared and subjected to immunoprecipitation (anti-Human VEGFR-2 ) followed by Western blotting (anti-Human VEGFR-2 antibody DM3523P). (Bernhard Barleon et.al., unpublished data!)
Figure 3: VEGFR-2/KDR Sandwich-ELISA using soluble KDR (D7) [ S01-002] as standard. Mouse anti-human VEGFR-2 was used as capture antibody, Biotinylated rabbit anti-human VEGFR-2 DP3509B was used for detection.